Chemotherapy for subjects with untreated Burkitt lymphoma

What we are studying

You are being asked to take part in this study because you have an aggressive B-cell lymphoma. The purpose of this study is to compare the good and/or bad effects of an experimental approach to treating your disease and to analyze your tumor using new scientific laboratory studies. Many of the standard treatments for Burkitt lymphoma can cause severe side effects that may require long stays in the hospital. Our experience using this treatment, Dose-Adjusted EPOCH +/- Rituximab (DA-EPOCH-R) has been that it has not been associated with the same severity of side effects or long durations in the hospital.

Who we are studying

  • Men and Women
  • Races:
    • White
    • African American
    • Asian
    • American Indian or Alaska Native
    • Native Hawaiian or Pacific Islander
    • Other
  • All Ethnicities
  • All Ages up to 90

Eligibility Criteria

  • Burkitt lymphoma or B-cell lymphoma

What is involved

  • Up to 6-8 cycles (cycle = 21 days) of chemotherapy

Compensation

None

Contact Information

Study Coordinator
Teresa Brady
Email
tbrady@wakehealth.edu
Phone
336-716-4703

Disclaimer: The information on this website is for general informational purposes only and SHOULD NOT be relied upon as a substitute for sound professional medical advice, evaluation or care from your physician or other qualified health care provider.